日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

DESTINY-Breast08:曲妥珠单抗德鲁替康联合其他抗癌疗法治疗HER2低表达转移性乳腺癌患者的Ib期研究

Jhaveri, Komal; Loi, Sherene; Hamilton, Erika; Schmid, Peter; Anders, Carey K; Testa, Laura; Wildiers, Hans; Tseng, Ling-Ming; Lu, Yen-Shen; Park, Yeon Hee; Im, Seock-Ah; Chen, Shin-Cheh; Young, Robyn R; Lloyd, Caron; Wrona, Magdalena; Zhang, Cuihong; Carroll, Danielle; André, Fabrice

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

PI3Kα抑制剂和降解剂Inavolisib可利用FGFR2增强PIK3CA突变实体瘤患者和临床前模型的疗效。

Juric Dejan, Song Kyung, Johnson Radia M, Accordino Melissa K, Bedard Philippe L, Cervantes Andrés, Gambardella Valentina, Hamilton Erika, Italiano Antoine, Kalinsky Kevin, Krop Ian E, Oliveira Mafalda, Saura Cristina, Schmid Peter, Turner Nicholas C, Varga Andreea, Gendreau Steven, Hwang Michael S, Kuang Zheng, Lau Jeffrey T, Lin Eva, Pham Trang, Maddalo Danilo, Rees Matthew G, Ronan Melissa M, Roth Jennifer A, Martin Scott, Sodir Nicole M, Sokol Ethan S, Whitfield Zachary J, Wong Alice, Yauch Robert L, Aimi Junko, Cheeti Sravanthi, Fredrickson Jill, Hilz Stephanie, Hafner Marc, Hutchinson Katherine E, Jin Yanling, Peters Ubong, Zingg Daniel, Royer-Joo Stephanie, Shankar Noopur, Schutzman Jennifer L, Jhaveri Komal L, Dey Anwesha

Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis

帕博利珠单抗治疗早期三阴性乳腺癌:KEYNOTE-522 日本亚组分析

Takahashi, Masato; Mukai, Hirofumi; Takano, Toshimi; Tsugawa, Koichiro; Inoue, Kenichi; Itoh, Mitsuya; Watanabe, Junichiro; Tanabe, Yuko; Yamamoto, Naohito; Miyoshi, Yasuo; Watanabe, Kenichi; Mukohara, Toru; Kong, Yibin; Shimura, Masashi; Beca, Francisco; Schmid, Peter; Iwata, Hiroji

OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy

OPERA-01:一项针对接受过 CDK4/6 抑制剂治疗的 ER+、HER2- 晚期乳腺癌患者的帕拉唑司群 III 期研究

Pistilli, Barbara; Bellet Ezquerra, Meritxell; Del Mastro, Lucia; Sohn, Joohyuk; Schmid, Peter; Meisel, Jane; Chan, Arlene; Zheng, Lianqing; de Kermadec, Elisabeth; McArthur, Heather

Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial

帕博利珠单抗联合化疗治疗高危早期ER(+)/HER2(-)乳腺癌:一项随机3期试验

Cardoso, Fatima; O'Shaughnessy, Joyce; Liu, Zhenzhen; McArthur, Heather; Schmid, Peter; Cortes, Javier; Harbeck, Nadia; Telli, Melinda L; Cescon, David W; Fasching, Peter A; Shao, Zhimin; Loirat, Delphine; Park, Yeon Hee; Fernandez, Manuel Gonzalez; Rubovszky, Gábor; Spring, Laura; Im, Seock-Ah; Hui, Rina; Takano, Toshimi; André, Fabrice; Yasojima, Hiroyuki; Ding, Yu; Jia, Liyi; Karantza, Vassiliki; Tryfonidis, Konstantinos; Bardia, Aditya

Challenges to Innovation Arising from Current Companion Diagnostic Regulations and Suggestions for Improvements

当前伴随诊断法规对创新带来的挑战及改进建议

Oliner, Kelly S; Shiller, Michelle; Schmid, Peter; Ratcliffe, Marianne J; Schetter, Aaron J; Tsao, Ming-Sound

Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer

早期三阴性乳腺癌患者新辅助化疗-免疫治疗后复发的时间

Licata, Luca; Mariani, Marco; Viale, Giulia; Dent, Rebecca; Tolaney, Sara M; Schmid, Peter; Hamilton, Erika; Sotiriou, Christos; Pusztai, Lajos; Bianchini, Giampaolo

Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy

潜在生物标志物与接受帕博利珠单抗或化疗治疗的转移性三阴性乳腺癌临床结局的关联

Cortes, Javier; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Lee, Keun Seok; Schmid, Peter; Tamura, Kenji; Testa, Laura; Ohtani, Shoichiro; Harbeck, Nadia; Loi, Sherene; Salgado, Roberto; Karantza, Vassiliki; Mejia, Jaime; Cristescu, Razvan; Loboda, Andrey; Nebozhyn, Michael; Jelinic, Petar; Huang, Lingkang; Winer, Eric P

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

高危早期三阴性乳腺癌患者新辅助帕博利珠单抗联合化疗疗效的分子决定因素:一项开放标签、多队列 1b 期 KEYNOTE-173 研究的探索性分析

Dent, Rebecca; Cortés, Javier; Park, Yeon Hee; Muñoz-Couselo, Eva; Kim, Sung-Bae; Sohn, Joohyuk; Im, Seock-Ah; Holgado, Esther; Foukakis, Theodoros; Kümmel, Sherko; Yearley, Jennifer; Wang, Anran; Nebozhyn, Michael; Huang, Lingkang; Cristescu, Razvan; Jelinic, Petar; Karantza, Vassiliki; Schmid, Peter

HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN

HER2低表达状态作为一种独特的乳腺癌亚型:是谬论还是事实?对WSG试验WSG-ADAPT-HR+/HER2-、WSG-PlanB和WSG-ADAPT-TN的分析

Schmidt, Gilda; Gluz, Oleg; Christgen, Matthias; Reinisch, Mattea; Kümmel, Sherko; Nitz, Ulrike; Braun, Michael; Aktas, Bahriye; Lüdtke-Heckenkamp, Kerstin; Forstbauer, Helmut; Grischke, Eva-Maria; Schumacher, Claudia; Mahlberg, Rolf; Malter, Wolfram; Reimer, Toralf; Nuding, Benno; Stefek, Andrea; Wuerstlein, Rachel; Graeser, Monika; Jóźwiak, Katarzyna; Burmeister, Sandy; Zu Eulenburg, Christine; Lauseker, Michael; Kolberg-Liedtke, Cornelia; Prat, Aleix; Schmid, Peter; Baehner, Rick; Kreipe, Hans Heinrich; Solomayer, Erich-Franz; Harbeck, Nadia